1887

Abstract

) is a major cause of urinary tract infections, bacteraemia, and sepsis. CFT073 is a prototypic, urosepsis isolate of sequence type (ST) 73. This laboratory, among others, has shown that strain CFT073 is resistant to serum, with capsule and other extracellular polysaccharides imparting resistance. The interplay of such polysaccharides remains under-explored. This study has shown that CFT073 mutants deficient in lipopolysaccharide (LPS) O-antigen and capsule display exquisite serum sensitivity. Additionally, O-antigen and LPS outer core mutants displayed significantly decreased surface K2 capsule, coupled with increased unbound K2 capsule being detected in the supernatant. The R1 core and O6 antigen are involved in the tethering of K2 capsule to the CFT073 cell surface, highlighting the importance of the R1 core in serum resistance. The dependence of capsule on LPS was shown to be post-transcriptional and related to changes in cell surface hydrophobicity. Furthermore, immunofluorescence microscopy suggested that the surface pattern of capsule is altered in such LPS core mutants, which display a punctate capsule pattern. Finally, targeting LPS biosynthesis using sub-inhibitory concentrations of a WaaG inhibitor resulted in increased serum sensitivity and decreased capsule in CFT073. Interestingly, the dependency of capsule on LPS has been observed previously in other , indicating that the synergy between these polysaccharides is not just strain, serotype or species-specific but may be conserved across several pathogenic Gram-negative species. Therefore, using WaaG inhibitor derivatives to target LPS is a promising therapeutic strategy to reduce morbidity and mortality by reducing or eliminating surface capsule.

Funding
This study was supported by the:
  • National Children's Research Centre (Award C/18/4)
    • Principle Award Recipient: StephenG.J. Smith
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author’s institution.
Loading

Article metrics loading...

/content/journal/micro/10.1099/mic.0.001493
2024-08-23
2024-11-10
Loading full text...

Full text loading...

/deliver/fulltext/micro/170/8/mic001493.html?itemId=/content/journal/micro/10.1099/mic.0.001493&mimeType=html&fmt=ahah

References

  1. Dale AP, Woodford N. Extra-intestinal pathogenic Escherichia coli (ExPEC): disease, carriage and clones. J Infect 2015; 71:615–626 [View Article] [PubMed]
    [Google Scholar]
  2. Miajlovic H, Smith SG. Bacterial self-defence: how Escherichia coli evades serum killing. FEMS Microbiol Lett 2014; 354:1–9 [View Article] [PubMed]
    [Google Scholar]
  3. Fratamico PM, DebRoy C, Liu Y, Needleman DS, Baranzoni GM et al. Advances in molecular serotyping and subtyping of Escherichia coli. Front Microbiol 2016; 7:644 [View Article]
    [Google Scholar]
  4. Miajlovic H, Cooke NM, Moran GP, Rogers TRF, Smith SG. Response of extraintestinal pathogenic Escherichia coli to human serum reveals a protective role for Rcs-regulated exopolysaccharide colanic acid. Infect Immun 2014; 82:298–305 [View Article] [PubMed]
    [Google Scholar]
  5. Sarkar S, Ulett GC, Totsika M, Phan MD, Schembri MA. Role of capsule and O antigen in the virulence of uropathogenic Escherichia coli. PLoS One 2014; 9:e94786 [View Article] [PubMed]
    [Google Scholar]
  6. Buckles EL, Wang X, Lane MC, Lockatell CV, Johnson DE et al. Role of the K2 capsule in Escherichia coli urinary tract infection and serum resistance. J Infect Dis 2009; 199:1689–1697 [View Article] [PubMed]
    [Google Scholar]
  7. Phan M-D, Peters KM, Sarkar S, Lukowski SW, Allsopp LP et al. The serum resistome of a globally disseminated multidrug resistant uropathogenic Escherichia coli clone. PLoS Genet 2013; 9:e1003834 [View Article] [PubMed]
    [Google Scholar]
  8. Kalynych S, Morona R, Cygler M. Progress in understanding the assembly process of bacterial O-antigen. FEMS Microbiol Rev 2014; 38:1048–1065 [View Article] [PubMed]
    [Google Scholar]
  9. McCabe WR, Kaijser B, Olling S, Uwaydah M, Hanson LA. Escherichia coli in bacteremia: K and O antigens and serum sensitivity of strains from adults and neonates. J Infect Dis 1978; 138:33–41 [View Article] [PubMed]
    [Google Scholar]
  10. Amor K, Heinrichs DE, Frirdich E, Ziebell K, Johnson RP et al. Distribution of core oligosaccharide types in lipopolysaccharides from Escherichia coli. Infect Immun 2000; 68:1116–1124 [View Article] [PubMed]
    [Google Scholar]
  11. Dissanayake DRA, Wijewardana TG, Gunawardena GA, Poxton IR. Distribution of lipopolysaccharide core types among avian pathogenic Escherichia coli in relation to the major phylogenetic groups. Vet Microbiol 2008; 132:355–363 [View Article] [PubMed]
    [Google Scholar]
  12. Leclercq SO, Branger M, Smith DGE, Germon P. Lipopolysaccharide core type diversity in the Escherichia coli species in association with phylogeny, virulence gene repertoire and distribution of type VI secretion systems. Microb Genom 2021; 7:000652 [View Article] [PubMed]
    [Google Scholar]
  13. Chakraborty A, Saralaya V, Adhikari P, Shenoy S, Baliga S et al. Characterization of Escherichia coli phylogenetic groups associated with extraintestinal infections in south Indian population. Ann Med Health Sci Res 2015; 5:241–246 [View Article] [PubMed]
    [Google Scholar]
  14. Kim KS, Itabashi H, Gemski P, Sadoff J, Warren RL et al. The K1 capsule is the critical determinant in the development of Escherichia coli meningitis in the rat. J Clin Invest 1992; 90:897–905 [View Article] [PubMed]
    [Google Scholar]
  15. van Alphen L, Arends A, Hopman C. Cross-reactions between Neisseria meningitidis group H and Escherichia coli K2 and K62 polysaccharides. J Clin Microbiol 1988; 26:394–396 [View Article] [PubMed]
    [Google Scholar]
  16. Hirschel B, Boulnois G, Timmis K. Neisseria meningitidis B and E. coli K1: different genes causing the production of an identical capsule. Preliminary communication. Schweiz Med Wochenschr 1983; 113:1857–1858 [PubMed]
    [Google Scholar]
  17. Whitfield C. Biosynthesis and assembly of capsular polysaccharides in Escherichia coli. Annu Rev Biochem 2006; 75:39–68 [View Article] [PubMed]
    [Google Scholar]
  18. Whitfield C. Structure and assembly of Escherichia coli capsules. EcoSal Plus 2009; 3: [View Article] [PubMed]
    [Google Scholar]
  19. Valle J, Da Re S, Henry N, Fontaine T, Balestrino D et al. Broad-spectrum biofilm inhibition by a secreted bacterial polysaccharide. Proc Natl Acad Sci U S A 2006; 103:12558–12563 [View Article] [PubMed]
    [Google Scholar]
  20. Goller CC, Seed PC. Revisiting the Escherichia coli polysaccharide capsule as a virulence factor during urinary tract infection: contribution to intracellular biofilm development. Virulence 2010; 1:333–337 [View Article] [PubMed]
    [Google Scholar]
  21. Lloyd AL, Henderson TA, Vigil PD, Mobley HLT. Genomic islands of uropathogenic Escherichia coli contribute to virulence. J Bacteriol 2009; 191:3469–3481 [View Article] [PubMed]
    [Google Scholar]
  22. Devine DA, Roberts AP. K1, K5 and O antigens of Escherichia coli in relation to serum killing via the classical and alternative complement pathways. J Med Microbiol 1994; 41:139–144 [View Article] [PubMed]
    [Google Scholar]
  23. Suerbaum S, Friedrich S, Leying H, Opferkuch W. Expression of capsular polysaccharide determines serum resistance in Escherichia coli K92. Zentralbl Bakteriol 1994; 281:146–157 [View Article] [PubMed]
    [Google Scholar]
  24. Rigg GP, Barrett B, Roberts I s. The localization of KpsC, S and T, and KfiA, C and D proteins involved in the biosynthesis of the Escherichia coli K5 capsular polysaccharide: evidence for a membrane-bound complex. Microbiology 1998; 144:2905–2914 [View Article]
    [Google Scholar]
  25. Taylor CM, Goldrick M, Lord L, Roberts IS. Mutations in the waaR gene of Escherichia coli which disrupt lipopolysaccharide outer core biosynthesis affect cell surface retention of group 2 capsular polysaccharides. J Bacteriol 2006; 188:1165–1168 [View Article] [PubMed]
    [Google Scholar]
  26. Diao J, Bouwman C, Yan D, Kang J, Katakam AK et al. Peptidoglycan association of murein lipoprotein is required for KpsD-dependent Group 2 capsular polysaccharide expression and serum resistance in a uropathogenic Escherichia coli isolate. mBio 2017; 8: [View Article]
    [Google Scholar]
  27. Jiménez N, Senchenkova SN, Knirel YA, Pieretti G, Corsaro MM et al. Effects of lipopolysaccharide biosynthesis mutations on K1 polysaccharide association with the Escherichia coli cell surface. J Bacteriol 2012; 194:3356–3367 [View Article] [PubMed]
    [Google Scholar]
  28. Singh S, Wilksch JJ, Dunstan RA, Mularski A, Wang N et al. LPS O antigen plays a key role in Klebsiella pneumoniae capsule retention. Microbiol Spectr 2022; 10:e0151721 [View Article] [PubMed]
    [Google Scholar]
  29. Fresno S, Jiménez N, Izquierdo L, Merino S, Corsaro MM et al. The ionic interaction of Klebsiella pneumoniae K2 capsule and core lipopolysaccharide. Microbiology 2006; 152:1807–1818 [View Article] [PubMed]
    [Google Scholar]
  30. Aldawood E, Roberts IS. Regulation of Escherichia coli Group 2 capsule gene expression: a mini review and update. Front Microbiol 2022; 13:858767 [View Article] [PubMed]
    [Google Scholar]
  31. Bao Y, Zhang H, Huang X, Ma J, Logue CM et al. O-specific polysaccharide confers lysozyme resistance to extraintestinal pathogenic Escherichia coli. Virulence 2018; 9:666–680 [View Article] [PubMed]
    [Google Scholar]
  32. Datsenko KA, Wanner BL. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A 2000; 97:6640–6645 [View Article] [PubMed]
    [Google Scholar]
  33. Goltermann L, Zhang M, Ebbensgaard AE, Fiodorovaite M, Yavari N et al. Effects of LPS composition in Escherichia coli on antibacterial activity and bacterial uptake of antisense peptide-PNA conjugates. Front Microbiol 2022; 13:877377 [View Article] [PubMed]
    [Google Scholar]
  34. Grozdanov L, Zähringer U, Blum-Oehler G, Brade L, Henne A et al. A single nucleotide exchange in the wzy gene is responsible for the semirough O6 lipopolysaccharide phenotype and serum sensitivity of Escherichia coli strain Nissle 1917. J Bacteriol 2002; 184:5912–5925 [View Article] [PubMed]
    [Google Scholar]
  35. Muheim C, Bakali A, Engström O, Wieslander Å, Daley DO et al. Identification of a fragment-based scaffold that inhibits the glycosyltransferase WaaG from Escherichia coli. Antibiotics 2016; 5:10 [View Article] [PubMed]
    [Google Scholar]
  36. Herlax V, de Alaniz MJT, Bakás L. Role of lipopolysaccharide on the structure and function of alpha-hemolysin from Escherichia coli. Chem Phys Lipids 2005; 135:107–115 [View Article] [PubMed]
    [Google Scholar]
  37. Phanphak S, Georgiades P, Li R, King J, Roberts IS et al. Super-resolution fluorescence microscopy study of the production of K1 capsules by Escherichia coli: evidence for the differential distribution of the capsule at the poles and the equator of the cell. Langmuir 2019; 35:5635–5646 [View Article] [PubMed]
    [Google Scholar]
  38. Manzoni M, Rollini M, Piran E, Parini C. Preliminary characterisation of an Escherichia coli K5 lyase-deficient strain producing the K5 polysaccharide. Biotechnol Lett 2004; 26:351–356 [View Article] [PubMed]
    [Google Scholar]
  39. Maffei E, Shaidullina A, Burkolter M, Heyer Y, Estermann F et al. Systematic exploration of Escherichia coli phage-host interactions with the BASEL phage collection. PLoS Biol 2021; 19:e3001424 [View Article] [PubMed]
    [Google Scholar]
  40. Gorzynski M, De Ville K, Week T, Jaramillo T, Danelishvili L. Understanding the phage-host interaction mechanism toward improving the efficacy of current antibiotics in Mycobacterium abscessus. Biomedicines 2023; 11:1379 [View Article] [PubMed]
    [Google Scholar]
  41. Chen Y, Li X, Wang S, Guan L, Li X et al. A novel tail-associated O91-specific polysaccharide depolymerase from a podophage reveals lytic efficacy of Shiga toxin-producing Escherichia coli. Appl Environ Microbiol 2020; 86:e00145-20 [View Article] [PubMed]
    [Google Scholar]
  42. Vihta K-D, Stoesser N, Llewelyn MJ, Quan TP, Davies T et al. Trends over time in Escherichia coli bloodstream infections, urinary tract infections, and antibiotic susceptibilities in Oxfordshire, UK, 1998-2016: a study of electronic health records. Lancet Infect Dis 2018; 18:1138–1149 [View Article] [PubMed]
    [Google Scholar]
  43. Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol 2010; 7:653–660 [View Article] [PubMed]
    [Google Scholar]
  44. Ciesielczuk H, Jenkins C, Chattaway M, Doumith M, Hope R et al. Trends in ExPEC serogroups in the UK and their significance. Eur J Clin Microbiol Infect Dis 2016; 35:1661–1666 [View Article] [PubMed]
    [Google Scholar]
  45. Hertz FB, Nielsen JB, Schønning K, Littauer P, Knudsen JD et al. Population structure of drug-susceptible,-resistant and ESBL-producing Escherichia coli from community-acquired urinary tract. BMC Microbiol 2016; 16:63 [View Article] [PubMed]
    [Google Scholar]
/content/journal/micro/10.1099/mic.0.001493
Loading
/content/journal/micro/10.1099/mic.0.001493
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error